Novavax has signed a non-binding heads of terms document with the Australian Government to supply 40 million doses of its Covid-19 vaccine candidate, NVX-CoV2373.

Created using Novavax’s recombinant protein nanoparticle technology, the vaccine candidate is a stable, prefusion protein that includes the company’s Matrix‑M adjuvant.

The vaccine candidate is currently in Phase III clinical trial in the UK.

On successful completion of the trial and after obtaining approval from Australia’s Therapeutic Goods Administration (TGA), Novavax will supply the vaccine doses to the country starting from the first half of next year.

Novavax president and CEO Stanley Erck said: “This arrangement with the Australian government reflects the importance of the ongoing clinical development of NVX-CoV2373 and will ensure that the citizens of Australia will have access to its supply.”

The vaccine regimen requires administering two doses for an individual 21 days apart.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Phase III global study will analyse NVX-CoV2373 in providing immunity, safety and for Covid-19 disease prevention.

For the trials, elderly people with underlying medical conditions, as well as diverse racial and ethnic representation, enrolled.

The company anticipates interim data from a late-stage trial of the vaccine by the first quarter of next year.

As well as progressing the clinical development, Novavax is manufacturing NVX-CoV2373 on a large scale across various locations worldwide.

So far, the company signed NVX-CoV2373 supply deals with the US, UK and Canada while the company will supply doses to Japan, South Korea and India through partnerships.

In July, Novavax received $1.6bn from the US government for the development and manufacturing of the vaccine candidate.

In addition, Coalition for Epidemic Preparedness Innovations (CEPI) agreed to provide up to $384m in funding to support the vaccine development.